One such fusion protein, (M7824), combines an anti-PD-L1 monoclonal antibody with two TGF-β receptor 2 molecules to serve as a TGF-β “Trap.” Urothelial cancer cell lines treated with this bispecific fusion protein demonstrated an increase in T-cell trafficking, TRAIL-mediated tumor lysis, and ADCC when compared to PD-L1 inhibition alone (39). The gene discussed is TGFB1; the disease is neoplasm.